Singular Genomics Showcases New G4X Spatial Sequencer At AGBT And Announces Significant Advances In Throughput, Quality, And Usability For G4 Sequencing Platform

Author: Benzinga Newsdesk | February 05, 2024 11:56am

Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced groundbreaking new products and capabilities at the Advances of Genome Biology and Technology (AGBT) conference in Orlando, Florida.

 

Singular unveiled the G4X™ Spatial Sequencer as a high-throughput in situ spatial sequencing platform capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H&E from formalin-fixed, paraffin-embedded (FFPE) tissues. As an upgrade to the G4® Sequencing Platform, the G4X is expected to position Singular to be the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument. The G4X Spatial Sequencer is on display at the conference, alongside performance data from technology access collaborations with top academic centers. The G4X is expected to be available as an upgrade to G4 customers by the end of 2024.

Singular also announced updates to the G4, the industry-leading benchtop sequencing system for speed, flexibility, and power.

• Development of a higher-throughput F4 Flow Cell, estimated to produce 600 million-800 million paired reads per flow cell, potentially doubling the G4 sequencer run output to 3.2 billion reads. The F4 flow cell is expected to be released in the second half of 2024.
• Increased sequencing quality with G4s runs now averaging above 90% bases ≥ Q30; raised specifications to 85% bases ≥ Q30.
• Showcased Singular Connect™, a web-based application for remote real-time monitoring of runs, results viewing, and instrument and team management.
  
   

Additionally, the company announced new programs and promotions for its product portfolio.

• Price reduction for the G4 Sequencing Platform from $350,000 to $295,000.
• G4X Early Adopter Promotional Package that includes the G4, G4X Services, and G4X Upgrade, Training and Warranty.
• Research grant programs for both the G4 and G4X.
• Spatial Technology Access Services on the G4X Spatial Sequencer.

"Today marks the beginning of an exciting new chapter for the company, as we drive to bring ultra-high-throughput spatial biology onto our existing sequencing platform," stated Drew Spaventa, Chief Executive Officer of Singular. "We are also excited to announce material updates to our sequencing portfolio in the form of higher throughput kits, improved accuracy, and a new remote user interface. In 2024, we look forward to shifting our focus to include clinical sequencing markets, and simultaneously to entering a new high-growth spatial biology market with the G4X."

Posted In: OMIC